Showing session: reset
Novel Immuno-oncology Agent Clinical Trials
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Introduction
Antoni Ribas
UCLA Medical Ctr., Los Angeles, CA, United States
- Free
- slides video
- audio + slides
- All slides included
The MITCI (Phase 1b) study: A novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy treatment
Brendan Curti
Providence Cancer Center, Providence Cancer Center, OR, United States
- Free
- slides video
- audio + slides
- All slides included
Phase 1b KEYNOTE 200 (STORM study): A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients
Charles Rudin
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
John C Bell
Ottawa Health Research Institute, Ottawa, ON, Canada
- Free
- slides video
- audio + slides
- All slides included
BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial
Lillian L Siu
Princess Margaret Cancer Centre, Toronto, ON, Canada
- Free
- slides video
- audio + slides
- All slides included
Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma
Yousef Zakharia
University of Iowa, Iowa City, IA, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Laura Q. M. Chow
Univ. of Washington, Seattle, WA, United States
- Free
- slides video
- audio + slides
- All slides included
T4 immunotherapy of head and neck squamous cell carcinoma using pan-ErbB targeted CAR T-cells
Sophie Papa
King's College London, London, United Kingdom
- Free
- slides video
- audio + slides
- All slides included
Discussant
Christian Hinrichs
National Cancer Inst., Bethesda, MD, United States
- Free
- slides video
- audio + slides
- All slides included
CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors
Leisha Emens
Johns Hopkins University, Baltimore, MD, United States
- Permission not
granted for presentation
Discussant
Bin Zhang
Northwestern Univ., Chicago, IL, United States